GlassScriptPhysician profile
Madeline Couch
NPI 1922642511
$2,530.49
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $478 · 2022: $423 · 2023: $1,253 · 2024: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,629.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $1,376.11 | 2021-2024 | Optune |
| Depuy Synthes Sales INC. | $124.31 | 2023 | Symphony |
| Genentech USA, INC. | $120.47 | 2022-2023 | Tecentriq |
| Seagen INC. | $101.15 | 2023 | Padcev, Adcetris |
| Foundation Medicine, INC. | $92.67 | 2023 | |
| Epizyme, INC. | $91.35 | 2021 | |
| Ucb, INC. | $76.44 | 2022-2024 | Briviact |
| Sanofi-Aventis U.S. LLC | $72.00 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $65.86 | 2023-2024 | Lynparza, Wainua, Calquence |
| Janssen Biotech, INC. | $45.37 | 2023-2024 | Erleada, Rybrevant, Akeega |
| E.R. Squibb & Sons, L.L.C. | $42.17 | 2023-2024 | Opdivo |
| Celgene Corporation | $40.15 | 2022-2024 | |
| Karyopharm Therapeutics INC. | $36.79 | 2023 | Xpovio |
| Amgen INC. | $35.63 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $34.43 | 2023 | Keytruda |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $25.42 | 2023 | Jakafi |
| Cti Biopharma Corp. | $24.96 | 2023 | Vonjo |
| Eisai INC. | $23.69 | 2023 | |
| Exelixis INC. | $22.45 | 2023 | Cabometyx |
| Gilead Sciences, INC. | $21.48 | 2023 | |
| Rigel Pharmaceuticals, INC. | $20.90 | 2023 | Rezlidhia, Tavalisse |
| Lilly USA, LLC | $19.86 | 2023 | Retevmo, Verzenio, Jaypirca |
| Novartis Pharmaceuticals Corporation | $16.83 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madeline Couch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.